Phase II trial of ISIS-APOCIII Rx in patients with severely high triglyceride levels and familial chylomicronaemia syndrome
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2014
Price : $35 *
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Isis Pharmaceuticals
- 04 Dec 2014 Results published in the New England Journal of Medicine.
- 04 Dec 2014 Status changed from active, no longer recruiting to completed, according to results published in NEJM.
- 03 Dec 2014 According to an Isis Pharmaceuticals media release, results were published in the New England Journal of medicine.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History